McDermott and Bull executive Search
 

Other News

HeartSciences Showcases MyoVista® Wavelet ECG at 2018 European Society of Cardiology Congress (ESC)

Rhythm by 0 comments

SOUTHLAKE, Texas–(BUSINESS WIRE)–HeartSciences, a medical device company developing next generation ECG devices using continuous wavelet transform (CWT) signal processing and artificial intelligence, is proud to announce its participation as an exhibitor at the upcoming 2018 European Society of Cardiology Congress (ESC). The Congress will take place at Messe Munich International […]

Continue Reading →

Boehringer Ingelheim: New sub-analyses to be presented at ESC Congress 2018 further support positive safety profile of Pradaxa® (dabigatran etexilate)

Coronary/Structural Heart Rhythm by 0 comments

NGELHEIM, Germany–(BUSINESS WIRE)–Boehringer Ingelheim today announced that it will present nine sub-analyses from the RE-DUAL PCITM trial and GLORIATM-AF Registry Program at the upcoming ESC Congress 2018, organised by the European Society of Cardiology, taking place in Munich, Germany on the 25-29 August 2018. The primary data from these studies have contributed […]

Continue Reading →

Capital Health First in New Jersey to Offer FDA-Approved EMBOTRAP II Stent Retriever for Ischemic Stroke Patients

Neuro by 0 comments

TRENTON, N.J., Aug. 20, 2018 /PRNewswire/ — Capital Health is the first hospital in New Jersey, and among the first in the United States, to use the new EMBOTRAP II Revascularization Device since its recent approval from the US Food and Drug Administration (FDA) in July. As part of its Comprehensive Stroke Center, neurosurgeons […]

Continue Reading →

Thrombosis Research Institute (TRI) to Announce New Real-World Insights in Atrial Fibrillation at ESC Congress 2018

Rhythm by 0 comments

MUNICH, August 20, 2018 /PRNewswire/ — Satellite symposium will highlight the breadth of evidence collected since the establishment of the registry in2009 An analysis of the comparative effectiveness of oral anticoagulants in everyday practice will be presented The economic burden of atrial fibrillation (AF) in nine European countries will be evaluated The […]

Continue Reading →

iSchemaView’s RAPID™ Approved for Use in Canada

Neuro by 0 comments

REDWOOD CITY, Calif.–(BUSINESS WIRE)–iSchemaView, the leader in cerebrovascular imaging analysis, today announced it has received final approval for the use of the RAPID platform in Canada. The RAPID platform is designed to provide physicians with fast, fully automated, elegant and easy-to-interpret imaging that facilitates clinical decision-making around cerebrovascular disease, such […]

Continue Reading →

CathWorks FAST-FFR Trial Enrollment Completed Early

Coronary/Structural Heart by 0 comments

KFAR-SABA, Israel–(BUSINESS WIRE)–CathWorks announced that its FAST-FFR trial is fully enrolled ahead of schedule. The trial is designed to evaluate efficacy of the CathWorks FFRangio™ System in terms of sensitivity and specificity when compared to conventional invasive Fractional Flow Reserve (FFR). Enrollment in the trial began on September 27, 2017 and […]

Continue Reading →

Cardurion Pharmaceuticals Appoints Jeb Keiper to Its Board of Directors

Financial by 0 comments

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Cardurion Pharmaceuticals, a biotechnology company focused on the development of novel, next-generation therapeutics for the treatment of cardiovascular diseases, today announced the appointment of industry leader, Jeb Keiper, as an independent member of its Board of Directors. Mr. Keiper joins founder Michael Mendelsohn, M.D., Ken Novack, Ed Mascioli, […]

Continue Reading →

New Data for Fantom in Heart Attack Patients to be Presented at the TCT 2018 Conference

Coronary/Structural Heart by 0 comments

SAN DIEGO, Aug. 15, 2018 (GLOBE NEWSWIRE) — REVA Medical, Inc. (ASX: RVA) (“REVA” or the “Company”), a leader in bioresorbable polymer technologies for vascular applications, will present new data on the use of the Fantom bioresorbable scaffold in patients experiencing heart attacks during the upcoming Transcatheter Cardiovascular Therapeutics (“TCT”) […]

Continue Reading →

Correvio Announces EU Survey Data Demonstrating Brinavess Successfully Avoided Hospitalization in 85% of Patients

Rhythm by 0 comments

VANCOUVER, Aug. 16, 2018 /PRNewswire/ – Correvio Pharma Corp. (NASDAQ: CORV) (TSX: CORV), a revenue-generating, specialty pharmaceutical company focused on providing innovative, high-quality brands that meet the needs of acute care physicians and patients, today reported positive data highlighting reduced hospitalization in patients treated with Brinavess® (vernakalant hydrochloride, IV), its antiarrhythmic drug for the […]

Continue Reading →
1 2 3 … 152